Reportlinker Adds IP Overview - "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010
NEW YORK, Sept. 21 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
In order to fight digestive system cancers, monoclonal antibody-based therapies have recently reinforced the range of already marketed treatments (mostly constituted of small molecules) and are generating important revenues. Four antibodies have already been approved but new ones are still needed. Many players are therefore trying to position themselves on this sector. This has resulted in an active patent policy that has nevertheless reached a plateau since 2005.
The present report analyses the patent environment and highlights the various monoclonal antibodies that have been developed to diagnose and treat oesophageal, gastric, bile duct, gastro-intestinal, colorectal, hepatic, pancreatic and anal cancers. The major trend is the development of human immunoconjugates against colorectal cancers by targeting growth factor receptors. Although this sector is surrounded by Roche and its subsidiaries, other players, and especially big pharma and biotech companies, continue to develop antibodies targeting new antigens and/or having new properties.
In this competitive sector driven by an important market and where 3000 patent families have been filed, this study « IP Overview – Monoclonal antibodies against digestive system cancers» provides you with a comprehensive panorama of the intellectual property landscape and he